Timothy Devos

20PUBLICATIONS
116CO-AUTHORS
Molecular targetsPredictive and prognostic markersAutonomic nervous systemHaematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|Mar 05, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, Francesca Palandri, Paola Guglielmelli

|Jan 13, 2026
Neutrophils as critical orchestrators of chronic inflammation.

Kaat Torfs, Gaël Vermeersch, Mieke Gouwy

|Aug 14, 2025
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry.

Timothy Devos, Dries Deeren, Koen Theunissen

|Nov 29, 2023
Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation.

Gaël Vermeersch, Timothy Devos, Helena Devos

|Oct 30, 2023
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.

Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano

Pageof 4

Frequent Collaborators

5 joint publications

Francesca Palandri

4 joint publications

Francesco Passamonti

4 joint publications

Jean-Jacques Kiladjian

4 joint publications

Alessandra Iurlo